{"filing":{"accession_number":"0001171843-26-004332","cik":"0001421642","ticker":"MSLE","company_name":"Satellos Bioscience Inc.","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"f6k_062926.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1421642/000117184326004332/f6k_062926.htm"},"events":[{"id":14444,"run_id":12857,"accession_number":"0001171843-26-004332","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces FDA Fast Track designation for SAT-3247 in Duchenne muscular dystrophy, a regulatory milestone that accelerates development and review timelines. While not a discrete M\u0026A, financing, or personnel event, the Fast Track designation—combined with existing Orphan Drug and Rare Pediatric Disease designations—materially advances the clinical program's regulatory pathway and represents a significant operational/strategic achievement for a clinical-stage biotech company. The designation is material to investors assessing the company's progress toward commercialization.","company_name":"Satellos Bioscience Inc.","ticker":"MSLE","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":[{"id":11879,"accession_number":"0001171843-26-004332","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA Fast Track designation for SAT-3247 in Duchenne muscular dystrophy, a regulatory milestone that accelerates development and review timelines. While not a discrete M\u0026A, financing, or personnel event, the Fast Track designation—combined with existing Orphan Drug and Rare Pediatric Disease designations—materially advances the clinical program's regulatory pathway and represents a significant operational/strategic achievement for a clinical-stage biotech company. The designation is material to investors assessing the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:02:37.407360+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11879,"accession_number":"0001171843-26-004332","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA Fast Track designation for SAT-3247 in Duchenne muscular dystrophy, a regulatory milestone that accelerates development and review timelines. While not a discrete M\u0026A, financing, or personnel event, the Fast Track designation—combined with existing Orphan Drug and Rare Pediatric Disease designations—materially advances the clinical program's regulatory pathway and represents a significant operational/strategic achievement for a clinical-stage biotech company. The designation is material to investors assessing the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:02:37.407360+00:00","company_name":"Satellos Bioscience Inc.","ticker":"MSLE","filing_date":"2026-06-29"}]}